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Supplementary Fig. S1 - Pipeline for exome/RNA analysis and neoepitope prediction.
2
Supplementary Fig. S2 - Pipeline for exome and clustering analysis of autochthonous 8101 tumor 
fragments.
3
Supplementary Fig. S3 - Generation of 1D9 T cells. A, Schematic representation of the 1D9 
retrovirus. The TCRα- and β-chain genes were introduced into the MP71-PRE retrovirus vector (see 
reference in (22)) linked by a 2A element. LTR: long terminal repeat of the mouse myeloproliferative 
sarcoma virus; 2A: 2A element of porcine teschovirus; PRE: post-transcriptional regulatory  element of 
the woodchuck hepatitis virus. B, Representative staining of blood samples from 1D9xRag-/- and 
C57BL/6 mice. Left panels show staining for CD4 and CD8. Numbers indicate percentage of CD8+ T 
cells of all lymphocytes. Expression of TCRvβ6 and the 1D9 TCR was detected using TCRvβ6-specific 
antibodies and H-2Kb:mp68 multimers, respectively. C, Cultured T cells derived from splenocytes of 
OT-IxRag-/- mice were analyzed for CD8 expression. 1D9 TCR expression was determined using 
TCRvβ6-specific antibodies before and after transduction with 1D9 retrovirus.
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Supplementary Fig. S4 - Generation of mp68-expressing tumor cell lines. A, Scheme of the 
retrovirus encoding the trimeric minigene SNFVFAGI-AAY fused to GFP (mp68-GFP). LTR: long 
terminal repeat of the mouse myeloproliferative sarcoma virus; PRE: post-transcriptional regulatory 
element of the woodchuck hepatitis virus. B, Flow cytometric analysis of mp68-GFP fusion proteins 
expressed by the transduced and sorted tumor cells MC57 and Bulk. Parental MC57 and Bulk 
(unmodified, gray) were analyzed for comparison. Numbers indicate percentage of mp68-GFP-
expressing cells.
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Supplementary Fig. S5 - Expansion of 1D9 T cells is antigen-specific and not driven by 
lymphopenia-induced proliferation. Splenocytes of YFPx1D9xRag-/- mice were transferred into 
H-2Kb-positive and H-2Kb-negative Rag-/- mice bearing MC57-mp68 or MC57-SIY tumors. 1D9 T 
cells were monitored in blood taken on day 2 and 6 after adoptive transfer. Numbers indicate the 
percentage of YFP+/TCRvβ6+ double-positive cells.
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Supplementary Fig. S6 - 1D9 T cells do not infiltrate tumors if mp68 is not expressed. A, 
Longitudinal imaging of an established MC57-SIY tumor grown in a Rag-/- mouse following adoptive 
transfer of 1D9 T cells of YFPx1D9xRag-/- mice. Day  0 is the first day on which T cell infiltration was 
found in animals with MC57-mp68 tumors in the same experiment (see Fig. 4A, left). At that time 
point, one T cell (pseudo-colored in red, see magnification) was visible in the blood stream. Viability  of 
tumor tissue was analyzed by monitoring GFP (cancer cells, green) and blood flow (DiD-stained 
erythrocytes, purple). B, Quantification of the areas shown in (A) that are covered by live cancer cells 
(green) and functional vessels (purple). Areas on day 0 were defined as 100%.
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Supplementary Table S1 - Results of whole exome sequencing of Bulk tumor cells and Bulk 
reisolates after 1D9 T cell therapy.
Sample
p68S551F p53S238A
Average 
depth
Nonsynonymous 
SNV Wild type Mutant VAF (%) Wild type Mutant VAF (%)
Heart-lung fibroblasts
Bulk
Reis#1
Reis#2
158 0 207 0 0 56 0 0
146 7,923 161 52 24 8 30 79
125 7,808 182 3 2 42 18 30
92 7,809 108 17 14 10 24 71
Reis: Reisolates
VAF: Variant allelic frequency
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Supplementary Table S2 - Results of whole exome sequencing of fragments derived from the 
autochthonous 8101 tumor.
Sample
p68S551F p53S238A
Average 
depth
Nonsynonymous 
SNV Wild type Mutant VAF (%) Wild type Mutant VAF (%)
Heart-lung fibroblasts
Frag#1
Frag#2
Frag#3
Frag#4
Frag#5
Frag#6
Frag#7
Frag#8
Frag#9
Frag#10
Frag#11
Frag#12
Frag#13
Frag#14
Frag#15
Frag#16
Frag#17
Frag#18
Frag#19
Frag#20
158 0 207 0 0 56 0 0
83 7,726 77 42 35 28 12 30
101 8,481 119 46 28 29 6 17
91 7,861 79 60 43 29 17 37
76 7,785 55 43 44 26 11 30
79 336 120 4 3 35 0 0
80 1,703 118 4 3 34 0 0
60 7,522 50 19 28 10 5 33
77 6,602 77 20 21 17 6 26
77 7,801 63 43 41 24 12 33
83 7,754 67 45 40 18 13 42
93 7,845 93 42 31 22 10 31
93 7,540 106 36 25 24 8 25
84 7,488 74 30 29 29 11 28
79 7,612 85 28 25 23 6 21
78 7,270 87 30 26 28 11 28
72 5,523 122 22 15 13 3 19
86 7,423 90 30 25 23 5 18
80 6,485 90 30 25 25 3 11
64 7,694 67 33 33 9 12 57
78 7,551 74 31 30 30 17 36
Frag: Fragment
VAF: Variant allelic frequency
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